Stockscreener 앱 받기
80.57
3.40%
2.65
시간 외 거래:
77.52
-3.05
-3.79%
전일 마감가:
$77.92
열려 있는:
$77.92
하루 거래량:
215.33K
Relative Volume:
1.09
시가총액:
$784.12M
수익:
-
순이익/손실:
$-4.98M
주가수익비율:
-61.14
EPS:
-1.3177
순현금흐름:
$-3.85M
1주 성능:
+10.25%
1개월 성능:
-9.13%
6개월 성능:
+104.03%
1년 성능:
+78.33%
1일 변동 폭
$74.95
$81.12
1주일 범위
$73.61
$81.12
52주 변동 폭
$23.18
$123.75
Bright Minds Biosciences Inc Stock (DRUG) Company Profile
Compare DRUG vs VRTX, REGN, ARGX, ALNY, ONC
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
DRUG
Bright Minds Biosciences Inc
|
80.57 | 758.33M | 0 | -4.98M | -3.85M | -1.3177 |
|
VRTX
Vertex Pharmaceuticals Inc
|
465.02 | 117.03B | 11.74B | 3.68B | 3.34B | 14.19 |
|
REGN
Regeneron Pharmaceuticals Inc
|
783.65 | 82.35B | 14.34B | 4.50B | 3.77B | 41.56 |
|
ARGX
Argen X Se Adr
|
833.54 | 51.64B | 3.06B | 1.28B | 447.35M | 19.67 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
308.48 | 42.58B | 3.21B | 43.57M | 221.36M | 0.2405 |
|
ONC
Beone Medicines Ltd Adr
|
346.42 | 38.87B | 4.98B | 69.60M | 525.67M | 0.5198 |
Bright Minds Biosciences Inc Stock (DRUG) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2025-09-08 | 개시 | BTIG Research | Buy |
| 2025-05-13 | 개시 | TD Cowen | Buy |
| 2025-05-07 | 개시 | Chardan Capital Markets | Buy |
| 2025-01-23 | 개시 | Piper Sandler | Overweight |
| 2025-01-10 | 개시 | Cantor Fitzgerald | Overweight |
| 2025-01-10 | 개시 | H.C. Wainwright | Buy |
| 2024-11-26 | 개시 | Robert W. Baird | Outperform |
모두보기
Bright Minds Biosciences Inc 주식(DRUG)의 최신 뉴스
Trading the Move, Not the Narrative: (DRUG) Edition - Stock Traders Daily
Bright Minds Biosciences Inc. (NASDAQ:DRUG) Receives Consensus Recommendation of "Moderate Buy" from Brokerages - MarketBeat
Bright Minds Biosciences Inc. (NASDAQ:DRUG) Receives Consensus Recommendation of “Moderate Buy” from Brokerages - Defense World
Bright Minds Biosciences (DRUG) Projected to Post Quarterly Earnings on Thursday - MarketBeat
Rally Mode: Is Bright Minds Biosciences Inc undervalued by DCF analysisJuly 2025 Technicals & AI Powered Market Entry Ideas - baoquankhu1.vn
Dow Update: Will Bright Minds Biosciences Inc. benefit from AI trendsWeekly Profit Recap & High Yield Equity Trading Tips - baoquankhu1.vn
How interest rate cuts could boost Bright Minds Biosciences Inc. stockJuly 2025 Sector Moves & Weekly Setup with ROI Potential - mfd.ru
Short Interest in Bright Minds Biosciences Inc. (NASDAQ:DRUG) Rises By 67.5% - MarketBeat
Wall Street Analysts Think Bright Minds Biosciences Inc. (DRUG) Could Surge 36.27%: Read This Before Placing a Bet - MSN
What are the risks of holding Olin CorporationJuly 2025 Decliners & AI Powered Buy/Sell Recommendations - baoquankhu1.vn
Several Bright Minds Biosciences Insiders Sell Shares Sending Potential Negative Signal - simplywall.st
Aug Big Picture: Is SSNC stock trending bullishJuly 2025 Big Picture & Advanced Swing Trade Entry Alerts - baoquankhu1.vn
(DRUG) Volatility Zones as Tactical Triggers - Stock Traders Daily
Price-Driven Insight from (DRUG) for Rule-Based Strategy - Stock Traders Daily
Bright Minds reports positive Phase 2 results for epilepsy drug By Investing.com - Investing.com Nigeria
New epilepsy study tests drug for adults whose seizures resist treatment - Stock Titan
Volume Summary: How Bright Minds Biosciences Inc. stock performs in high volatility markets - Bộ Nội Vụ
Bright Minds Biosciences Inc. (NASDAQ:DRUG) Receives Consensus Recommendation of "Moderate Buy" from Analysts - MarketBeat
Why Bright Minds Biosciences Stock Topped the Market on Monday - MSN
Bright Minds Biosciences closes $175 million public offering By Investing.com - Investing.com Nigeria
Warm welcome for Aktis could open up IPO queue: Public Equity Report - BioCentury
Bright Minds Biosciences (NASDAQ:DRUG) Cut to "Sell" at Wall Street Zen - MarketBeat
Bright Minds Biosciences Raises US$175 Million in Share Offering to Advance CNS Drug Pipeline - TipRanks
Bright Minds prices $175M stock offering - MSN
Bright Minds Biosciences Reports Phase 2 BMB-101 Data: 73% Median Drop in Absence Seizures on EEG - MarketBeat
Bright Minds Biosciences Closes its US$175 Million Public Offering - marketscreener.com
McMillan Advises Bright Minds Bioscience on its USD$175 Million Prospectus Offering - McMillan LLP
Bright Minds Biosciences closes $175 million public offering - Investing.com
Bright Minds Biosciences Closes $175.1 Million Stock Offering - marketscreener.com
Bright Minds Biosciences Announces Closing of US$175 Million Public Offering - manilatimes.net
Star TribuneBright Minds Biosciences Announces Closing of US$175 Million Public Offering - FinancialContent
Bright Minds Biosciences Launches $175 Million Share Offering to Fund Neurology Drug Pipeline - TipRanks
Bright Minds Biosciences (NASDAQ: DRUG) launches $175M equity raise for trials - Stock Titan
Can Bright Minds Biosciences Inc. stock sustain free cash flow growthBreakout Watch & High Conviction Investment Ideas - ulpravda.ru
How Bright Minds Biosciences Inc. stock responds to policy changesWeekly Volume Report & Daily Oversold Bounce Ideas - Улправда
Bright Minds Biosciences slips after increased $175 mln stock sale - TradingView — Track All Markets
Bright Minds Biosciences Prices Upsized US$175 Million Public Offering and Ends ATM Program - TipRanks
Bright Minds Biosciences prices public offering at $90 per share By Investing.com - Investing.com Nigeria
Bright Minds Biosciences prices $175 million public offering By Investing.com - Investing.com Nigeria
Why Bright Minds Biosciences Inc. stock is popular among millennialsSector ETF Performance & AI-Driven Stock Forecast Models - Улправда
Bright Minds Biosciences stock price target raised to $147 by BTIG By Investing.com - Investing.com Canada
Bright Minds Biosciences prices public offering at $90 per share - Investing.com
Bright Minds Biosciences Announces Pricing of Upsized US$175 Million Public Offering of Common Stock - The Manila Times
Bright Minds Biosciences announces pricing of upsized US$175 million public offering of common stock at $90.00 per share - marketscreener.com
Bright Minds Biosciences launches $100 million public offering - MSN
Bright Minds Biosciences Ends Equity Distribution Deal With Piper Sandler and Cantor - TipRanks
Form FWP BRIGHT MINDS BIOSCIENCES Filed by: BRIGHT MINDS BIOSCIENCES INC. - StreetInsider
Bright Minds Biosciences: Positive BREAKTHROUGH Study Data Warrants 'Strong Buy' Rating - Seeking Alpha
Crude Oil Down 2%; ISM Services PMI Surges In December - Benzinga
Why Did DRUG Stock Rocket 51% Today? - Asianet Newsable
Bright Minds Biosciences Inc (DRUG) 재무 분석
매출
순이익
현금흐름
주당 순 이익
1.24%
0.19%
자본화:
|
볼륨(24시간):